Screening for Ovarian Response Variability Before Fertility Treatment

Abstract

Ovarian response variability plays a pivotal role in the outcomes of assisted reproductive technology (ART). Accurate pre-treatment screening for ovarian response is essential to optimize individualized fertility protocols, minimize risks, and enhance clinical success rates. This review synthesizes current evidence regarding the determinants, assessment modalities, and clinical implications of ovarian response variability, offering up-to-date guideline-based recommendations for clinicians managing women undergoing fertility treatment.

Introduction

Ovarian response to controlled ovarian stimulation (COS) is a cornerstone determinant of success in ART, particularly in in vitro fertilization (IVF) cycles. Substantial inter-individual variability exists in ovarian response, influenced by both intrinsic and extrinsic factors. Early identification of women at risk for poor or excessive ovarian response enables clinicians to tailor stimulation regimens, mitigate complications such as ovarian hyperstimulation syndrome (OHSS), and improve reproductive outcomes. This article critically reviews the assessment, determinants, and management of ovarian response variability, emphasizing evidence-based strategies for pre-treatment screening.

Epidemiology / Disease Burden

Globally, infertility affects approximately 8-12% of reproductive-aged couples, with ART utilization on the rise. Up to one-third of women undergoing IVF demonstrate unexpected poor or suboptimal ovarian responses, while 5-10% may exhibit excessive responses leading to OHSS. Poor ovarian response is associated with reduced oocyte yield, compromised embryo quality, and lower live birth rates, highlighting the clinical importance of early and accurate risk stratification. Conversely, hyper-response increases the likelihood of cycle cancellation and adverse events, imposing significant healthcare burdens and psychosocial impacts.

Pathophysiology

Ovarian response variability is underpinned by the dynamic interplay between ovarian reserve, folliculogenesis, and endocrine signaling. Ovarian reserve reflects the quantity and quality of primordial follicles, predominantly determined by age, genetics, and environmental exposures. Follicle-stimulating hormone (FSH) sensitivity varies based on granulosa cell function and intra-ovarian signaling pathways. Reduced ovarian reserve leads to attenuated follicular recruitment and lower oocyte yield, whereas heightened FSH sensitivity or polycystic ovarian morphology predisposes to hyper-response. Molecular markers, such as anti-Müllerian hormone (AMH) and antral follicle count (AFC), offer mechanistic insights into the ovarian follicular pool and response potential.

Risk Factors

Multiple factors contribute to ovarian response variability. Advanced maternal age and diminished ovarian reserve are the principal risk factors for poor response. Previous ovarian surgery, endometriosis, chemotherapy, and genetic variants (e.g., FSH receptor polymorphisms) further increase risk. Conversely, younger age, polycystic ovary syndrome (PCOS), elevated AMH levels, and high AFC are linked to excessive response. Ethnicity, body mass index (BMI), and environmental exposures may also modulate ovarian responsiveness, necessitating individualized assessment during pre-treatment counseling.

Clinical Features

Poor ovarian response is typically characterized by low estradiol levels during stimulation, reduced number of developing follicles, and retrieval of fewer than four oocytes. Hyper-responders may present with rapid follicular growth, high estradiol concentrations, and clinical signs of OHSS, including abdominal distention, ascites, and electrolyte disturbances. Both hypo- and hyper-response can adversely impact cycle outcomes and patient safety, underscoring the importance of vigilant clinical monitoring and early recognition of atypical responses during ART cycles.

Diagnosis

Screening for ovarian response variability relies on a combination of clinical history, serum biomarkers, and ultrasound assessment. Basal FSH, AMH, and AFC are the most widely validated predictors of ovarian reserve and response. AMH levels above 3.5 ng/mL and AFC above 15 are indicative of high response risk, while AMH below 1 ng/mL and AFC under 5 suggest poor reserve. Ovarian volume, inhibin B, and dynamic tests (e.g., clomiphene challenge, exogenous FSH stimulation) offer additional, though less commonly used, diagnostic value. Integrating these parameters into prediction models enhances risk stratification and individualized protocol selection.

Treatment & Management

Personalized ovarian stimulation protocols are central to optimizing outcomes based on pre-screened ovarian response risk. Poor responders may benefit from higher gonadotropin doses, use of recombinant FSH, or adjuvant therapies such as growth hormone or androgens, although evidence remains mixed. In hyper-responders, lower starting doses, use of GnRH antagonists, and trigger with GnRH agonist instead of hCG reduce OHSS risk. Cycle segmentation strategies, such as freeze-all approaches, may be employed in high-risk cases. Close ultrasound and hormone monitoring during stimulation are essential to enable timely intervention and minimize complications.

Recent Advances / Emerging Therapies

Recent years have seen the emergence of advanced algorithms incorporating genetic, proteomic, and machine learning data to refine ovarian response prediction. AMH and AFC remain the mainstays, but incorporation of FSH receptor genotyping and predictive modeling enhances accuracy. Individualized controlled ovarian stimulation (iCOS) protocols, guided by validated algorithms, are increasingly being adopted in clinical practice. Novel adjuvants, such as kisspeptin and growth hormone, are under investigation to improve response in poor prognosis patients. Ongoing research into ovarian tissue biomarkers and artificial intelligence-driven decision support platforms holds promise for further individualization of fertility treatment.

Guideline Recommendations

International guidelines from ESHRE, ASRM, and NICE recommend systematic assessment of ovarian reserve using AMH and AFC as first-line tools before ART. Individualized stimulation protocols are advocated based on predicted response, with clear thresholds for dose adjustment and trigger selection. Prophylactic measures, such as elective freeze-all or coasting, should be considered for high-risk hyper-responders. Clinicians are advised to engage in shared decision-making, providing patients with evidence-based information about risks, benefits, and expected outcomes tailored to their ovarian reserve status.

Conclusion

Effective screening for ovarian response variability is fundamental to the safe and successful application of fertility treatments. Incorporating predictive biomarkers, clinical risk factors, and individualized stimulation strategies enhances clinical outcomes and minimizes adverse events. Ongoing advances in biomarker discovery, genetic profiling, and decision support technologies are poised to further refine fertility care, underscoring the need for continued research and guideline updates to ensure optimal patient-centered management.